Literature DB >> 19059518

Adaptation and validation of the quality-of-life scale: Satisfaction with Life Domains Scale by Baker and Intagliata.

Janina Carlson1, Susana Ochoa, Josep Maria Haro, Gemma Escartín, Maribel Ahuir, Alfonso Gutierrez-Zotes, Manel Salamero, Joaquim Valero, Silvia Cañizares, Miquel Bernardo, Jose Cañete, Pedro Gallo.   

Abstract

OBJECTIVES: There are few quality-of-life instruments specifically for schizophrenia; thus, the objective of our study is to adapt and validate the Satisfaction with Life Domains Scale (SLDS) by Baker and Intagliata.
METHOD: This is a validation study in which the subjects were evaluated on 2 occasions (24-48 hours). The sample is composed of people with schizophrenia from 18 to 65 years old and who were seen in one of the following centers: Sant Joan de Déu-SSM, Hospital Clínic, Hospital de Mataró and Hospital Pere Mata. The SLDS was administered, along with Positive and Negative Syndrome Scale, the Clinical General Impression for Schizophrenia, Global Assessment of Function, Disability Assessment Scale--short version, Beck Cognitive Insight, and the Strauss and Carpenter Prognostic Scale. The Cronbach alpha test was carried out, and the intraclass correlation coefficient was used to assess test-retest reliability, along with Pearson correlations for discriminating validity.
RESULTS: The intraclass correlation coefficients oscillated between 0.51 and 0.83. The SLDS did correlate with any of the other instruments with the exception of the Positive and Negative Syndrome Scale general subscale and the Strauss and Carpenter prognostic scale.
CONCLUSIONS: The Spanish version of the SLDS was shown to be valid and reliable and provides a fast and specific measure for schizophrenia.

Entities:  

Mesh:

Year:  2008        PMID: 19059518     DOI: 10.1016/j.comppsych.2008.05.008

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  6 in total

Review 1.  Assessment of cognitive insight: a qualitative review.

Authors:  Sally E Riggs; Paul M Grant; Dimitri Perivoliotis; Aaron T Beck
Journal:  Schizophr Bull       Date:  2010-08-06       Impact factor: 9.306

2.  Assessing cognitive insight in nonpsychiatric individuals and outpatients with schizophrenia in Taiwan: an investigation using the Beck Cognitive Insight Scale.

Authors:  Yu-Chen Kao; Tzong-Shi Wang; Chien-Wen Lu; Yia-Ping Liu
Journal:  BMC Psychiatry       Date:  2011-10-21       Impact factor: 3.630

3.  Study protocol of a randomised clinical trial testing whether metacognitive training can improve insight and clinical outcomes in schizophrenia.

Authors:  Javier-David Lopez-Morinigo; Verónica González Ruiz-Ruano; Adela Sánchez Escribano Martínez; María Luisa Barrigón Estévez; Laura Mata-Iturralde; Laura Muñoz-Lorenzo; Sergio Sánchez-Alonso; Antonio Artés-Rodríguez; Anthony S David; Enrique Baca-García
Journal:  BMC Psychiatry       Date:  2020-01-29       Impact factor: 3.630

4.  Investigating the Role of Insight, Decision-Making and Mentalizing in Functional Outcome in Schizophrenia: A Cross-Sectional Study.

Authors:  Paula Jhoana Escobedo-Aedo; Ana Forjan-González; Adela Sánchez-Escribano Martínez; Verónica González Ruiz-Ruano; Sergio Sánchez-Alonso; Laura Mata-Iturralde; Laura Muñoz-Lorenzo; Enrique Baca-García; Anthony S David; Javier-David Lopez-Morinigo
Journal:  Behav Sci (Basel)       Date:  2022-01-27

5.  Smartphone-based Ecological Momentary Intervention for secondary prevention of suicidal thoughts and behaviour: protocol for the SmartCrisis V.2.0 randomised clinical trial.

Authors:  Maria Luisa Barrigon; Alejandro Porras-Segovia; Philippe Courtet; Jorge Lopez-Castroman; Sofian Berrouiguet; María-Mercedes Pérez-Rodríguez; Antonio Artes; Enrique Baca-Garcia
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

Review 6.  Health related quality of life in patients having schizophrenia negative symptoms - a systematic review.

Authors:  Chiraz Azaiez; Aurélie Millier; Christophe Lançon; Emilie Clay; Pascal Auquier; Pierre-Michel Llorca; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2018-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.